Register

Hematologic Malignancies

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

In 2024, do you consider isolated gain(1q) [not amp(1q)] to be a high-risk cytogenetic abnormality in multiple myeloma?
Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with ...
1 Answer available
How long should we treat patients with newly diagnosed myeloma with bisphosphonates or RANKL inhibitors for their myeloma bone disease given recent data?
The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...
1 Answer available
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
1 Answer available
Is there any value to getting a bone marrow biopsy at the time of biochemical relapse in multiple myeloma before switching to a new line of therapy?
For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?
3 Answers available
Do you resume zoledronic acid or denosumab at relapse in multiple myeloma?
Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...
2 Answers available
For patients on commercial teclistamab who achieve a response, are there patient-specific or response-specific parameters that would prompt you to de-escalate therapy from once per week?
For example - minimum number of months of therapy, driving distance to clinic, at least a CR with or without MRD negativity?
3 Answers available
How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?
Would you continue R-CHOP or would you switch therapy? 
1 Answer available
For a Jehovah's Witness patient with multiple myeloma, could you safely offer a BCMA-directed bispecific antibody or CAR-T therapy?
Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).
2 Answers available
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
1 Answer available
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
1 Answer available
Are there any circumstances where you recommend early institution of systemic therapy for patients with solitary plasmacytoma?
Specifically, do you offer closer follow-up for certain patients after local radiation?
3 Answers available
How would you manage biopsy-proven DLBCL in a patient who was treated with 6 cycles of R-CHOP 15 years ago for DLBCL?
Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure? 
1 Answer available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
2 Answers available
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
1 Answer available
Do you recommend utilizing daratumumab in the maintenance phase after a quadruplet induction for transplant eligible multiple myeloma?
3 Answers available
How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?
Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?
2 Answers available
How extensive of a workup do you do for systemic AL amyloidosis for a patient with a resected amyloidoma, localized AL amyloid deposition in their airway or lungs, who has no other symptoms?
Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?
3 Answers available
How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?
Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing. 
1 Answer available
For a patient with triple-class-refractory myeloma and cytopenias who has been collected for CAR-T, would you choose aggressive chemotherapy or a bispecific antibody for bridging?
This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...
2 Answers available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?
1 Answer available
What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?
4 Answers available
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
5 Answers available
How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?
I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.
3 Answers available
How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?
1 Answer available
For patients who require aggressive debulking in multiple myeloma, what is your preferred chemotherapy regimen and why?
Modified HyperCVAD? V(R)D-PACE? DCEP? Are there any data to favor one over the other?
2 Answers available
How do you manage IgM related peripheral neuropathy?
Do you utilize rituximab or any other specific management strategies?
2 Answers available
How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?
Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion? 
2 Answers available
How do you approach post-transplant maintenance for patients with high-risk myeloma?
Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...
2 Answers available
Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?
If so, why?
4 Answers available
Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?
3 Answers available
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
1 Answer available
Do you always start treatment for patients who meet diagnostic criteria for multiple myeloma by SLiM criteria alone?
i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion
2 Answers available
Do you change treatment for confirmed biochemical progression in patients with otherwise secretory MM even if the M-spike is <0.5 g/dL?
3 Answers available
How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
2 Answers available
How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?
Would your approach differ for a 30 year old and a 70 year old?
3 Answers available
What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?
Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...
1 Answer available
What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?
2 Answers available
In light of the TRIANGLE data at ASH, how are you now approaching a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?
Are you adding ibrutinib? Should we add ibrutinib to NORDIC? Still referring to transplant? 
2 Answers available
How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?
How do you choose between CAR-T and autoSCT, for example? 
3 Answers available
How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?
1 Answer available
Is there still a role for plasma exchange/PLEX for confirmed or suspected cast nephropathy in multiple myeloma to rapidly reduce light chain burden?
In addition to reversing hypercalcemia, initiating myeloma therapy, etc.
1 Answer available
How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?
Would you still go to auto or consider allo? 
1 Answer available
How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?
Would you intercalate HD-MTX with her CHOEP?
1 Answer available
Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?
Ide-cel? Cilta-cel? Teclistamab?
1 Answer available
For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?
For example, would you use a tool like the Hydrashift assay? Would this change your management? 
1 Answer available
When you use selinexor for relapsed/refractory myeloma, with what total weekly dose do you practically start?
If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...
1 Answer available
What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?
2 Answers available
What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?
2 Answers available
What is your approach to pRBC transfusion support for myeloma-related anemia?
How much weight do you give to a hgb/hct threshold versus symptoms?
3 Answers available
What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?
1 Answer available
If you treat a patient with high-risk smoldering myeloma on trial and they develop biochemical progression by M-spike, but still no CRAB-SLiM criteria, what would you do next?
In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...
1 Answer available
Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?
2 Answers available
How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?
2 Answers available
What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?
2 Answers available
What induction regimen would you choose for a patient with newly diagnosed multiple myeloma with incidental amyloidosis noted on bone marrow biopsy, but with no end-organ damage as a result of amyloid deposition?
Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd? 
4 Answers available
What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?
2 Answers available
How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?
1 Answer available
What treatment would you recommend in an older patient with multiply relapsed double-hit lymphoma with recurrence following ASCT, pola-BR, and CAR-T therapy?
1 Answer available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?
1 Answer available
How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?
1 Answer available
How would you approach therapy for a patient with smoldering multiple myeloma whose light chain ratio has increased to greater than 100 over several years in the absence of any other myeloma-defining events?
Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...
2 Answers available
How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?
1 Answer available
How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?
Would you give R-CHOP without knowing if there was use of prior anthracycline? 
1 Answer available
For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
What is your experience with using Frailty Index or other geriatric screening in making decisions for elderly patients with multiple myeloma?
Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?
2 Answers available
In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?
Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...
3 Answers available
How do you approach patients with recurrent grade 3+ neutropenia on IMiD-containing regimens (e.g., VRd or KRd) beyond dose reductions?
For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.
1 Answer available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
Which patients with smoldering myeloma do you treat?
2 Answers available
How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
2 Answers available
What is the optimal prophylaxis regimen to use prior to a selinexor based regimen in the treatment of multiple myeloma for nausea and electrolyte abnormalities? 
2 Answers available
How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?
Ki67  = 90% with multiple small nodes on PET scan and normal CBC
1 Answer available
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
2 Answers available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available
How do you approach a patient with an anaplastic plasmacytoma without systemic evidence of disease in the bone marrow?
What about multiple anaplastic plasmacytoma without bone marrow involvement?
2 Answers available
Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?
Would you use MRD status to guide your decision making? 
1 Answer available
What is your preferred maintenance strategy for high risk multiple myeloma?
2 Answers available
What is the preferred regimen for AYA patients with T-Cell Lymphoblastic Lymphoma?
1 Answer available
Should a teenager diagnosed with CML in blast crisis go to transplant once MRD is negative?
2 Answers available
What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?
1 Answer available


Papers discussed in this category

Eur J Haematol, 2023 Mar 27
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
N. Engl. J. Med., 2018-01-25
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Biol Blood Marrow Transplant, 2019 Jul 01
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.
Ann Hematol, 2015 Mar 27
Management of chronic myeloid leukemia in blast crisis.
Leukemia, 2008-12
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Nature communications, 2019-04-23
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Blood, 2012 Aug 13
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
J Clin Oncol, 2020 Apr 16
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Blood,
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The Lancet. Oncology, 2019-01
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Blood,
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
The Lancet. Oncology, 2018-07
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Blood Cancer J, 2020 Mar 09
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
JAMA Oncol,
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA, 2016-11-15
Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.
N Engl J Med,
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
J Clin Oncol, 2019 Apr 10
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
J Clin Oncol, 2020 Feb 21
Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
J Clin Oncol, 2020 Oct 06
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Journal of clinical pathology, 2017-09
Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
Leukemia, 2018-06
Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.
Haematologica, 2021 Jun 01
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Outcome of deferred initial therapy in mantle-cell lymphoma.
The New England journal of medicine, 2015-11-05
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Haematologica, 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Blood,
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Leukemia, 2011 Jul 01
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Haematologica, 2019 Sep 19
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Blood, 2017 Aug 17
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood, 2015 May 28
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Clin Lymphoma Myeloma Leuk, 2020 Mar 07
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Clin Lymphoma Myeloma Leuk, 2021 Jul 18
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
Blood Cancer J, 2021 Jan 11
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Blood cancer journal, 2018-06-12
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
J. Clin. Oncol., 2019 Oct 25
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
JAMA Oncol,
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Blood, 2011-09-15
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Haematologica, 2011 Dec 01
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Cancer Chemother Pharmacol, 2016 Jun 10
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Clin Cancer Res, 2020 Aug 17
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.
British journal of haematology, 2017-11
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
J Clin Oncol, 2016 Feb 29
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Lancet Haematol, 2016 Dec 05
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Oncol, 2022 Jan 21
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
N Engl J Med,
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Lancet Oncol, 2020 Oct 29
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
J Clin Oncol, 2021 Aug 13
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Blood Adv, 2021 Sep 01
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood, 2015-03-26
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Clin Lymphoma Myeloma Leuk, 2019 Oct 09
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
JCO Oncol Pract, 2019 Nov 25
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.
Lancet Haematol,
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Leukemia, 2020 Jul 21
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Lancet (London, England), 2019-01-19
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Lancet Oncol, 2014 Oct 26
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Blood cancer journal, 2016-07-29
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Leukemia, 2022 Apr 11
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
J Clin Oncol, 2022 Dec 22
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Blood Adv, 2022 May 10
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Blood, 2022 Dec 15
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
Blood, 2016 Mar 21
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Amyloid, 2017 Apr 23
Amyloid in bone marrow smears in systemic light-chain amyloidosis.
Leukemia, 2015 Oct 07
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
British journal of haematology, 2017-10
Natural history of amyloidosis isolated to fat and bone marrow aspirate.
Blood Adv,
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Blood Cancer J, 2018 May 24
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Amyloid, 2019 Jan 20
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Proc Natl Acad Sci U S A, 2019 Apr 15
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
N Engl J Med,
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med,
GPRC5D-Targeted CAR T Cells for Myeloma.
Ann Oncol, 2009 Jul 01
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood, 2010 Jul 21
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Clin Lymphoma Myeloma Leuk, 2020 Jul 29
Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
Br J Haematol, 2021 Aug 15
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Blood, 2022 Dec 08
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
N Engl J Med, 2022 Jun 05
Teclistamab in Relapsed or Refractory Multiple Myeloma.
J Clin Oncol, 2022 Jun 04
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
J Clin Oncol, 2022 Oct 21
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Leukemia, 2019-03
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Journal of the American Society of Nephrology : JASN, 2007-03
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Lancet Haematol, 2019 Mar 11
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
Blood Cancer J, 2022 Sep 02
Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.
N Engl J Med, 2022 Jun 03
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
J Hematol Oncol, 2021 Oct 30
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Blood, 2022 Mar 03
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Lancet,
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
N Engl J Med, 2021 Dec 11
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Cancer, 2021 Jun 28
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Leukemia, 2022 Feb 21
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
Cancer cell, 2017-06-12
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
J Neurooncol, 2022 Jun 20
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
Lancet Oncol, 2020 Jun 05
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol, 2022 Jul 12
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet, 2021 Jun 24
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
N Engl J Med, 2023 Jun 05
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med, 2023 Feb 10
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Lancet Oncol, 2021 Dec 03
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet, 2021 Jun 04
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Blood, 2022 Oct 20
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
J Clin Oncol, 2017 Jan 17
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Br J Haematol, 2023 Jun 07
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Experimental hematology & oncology, 2022 Feb 28
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
American journal of hematology, 2022 Jul 05
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Blood advances, 2023 Oct 24
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Blood, 2018 Aug 14
Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
Haematologica, 2013-01
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.
The Lancet. Haematology, 2015 May 06
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06
The lung in amyloidosis.
Mayo Clinic proceedings, 2017-06
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.
Blood Cancer J, 2022 Sep 14
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
The Lancet. Haematology, 2023 Sep 11
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
The Lancet. Oncology, 2021 Sep 13
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
The New England journal of medicine, 2019-05-30
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
Blood, 2023 Nov 30
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Cancer, 2011-10-01
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
BMC Cancer, 2006 May 05
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
International journal of radiation oncology, biology, physics, 1998-07-15
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.
International journal of radiation oncology, biology, physics, 2006-01-01
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.
Blood, 2014 May 29
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.
Blood, 2014 Jun 17
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.
International journal of radiation oncology, biology, physics, 2011 Jan 27
Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy.
Leukemia & lymphoma, 2021 Feb 03
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
Dominion law reports, 1990 Mar 30
Malette v. Shulman.
Blood, 2020 Apr 09
Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.
American journal of hematology, 2019-04
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Blood advances, 2023 Mar 28
Outcomes after biochemical or clinical progression in patients with multiple myeloma.
American journal of hematology, 2023 Jul 08
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Blood, 2013-10-24
The impact of response on bone-directed therapy in patients with multiple myeloma.
The Lancet. Oncology, 2018-03
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Blood cancer journal, 2024 Apr 15
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Blood cancer journal, 2019 Nov 25
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
British journal of haematology, 2019 Dec 09
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
The New England journal of medicine, 2023 Dec 12
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Blood cancer journal, 2024 Apr 22
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Related Topics in Hematologic Malignancies

Copyright © 2024 theMednet
All Rights Reserved.